Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 450 of 2051 entries
View as:

GARDASIL Reexamination Study (V501-059)

Phase: N/A Priority: Normal
NCT ID: NCT01062074 Org: User:
Start: 09/28/07 End: 05/07/13 Due: 05/07/14

Osteoporosis Disease Management Demonstration Project (0000-037)

Phase: N/A Priority: Normal
NCT ID: NCT00139425 Org: User:
Start: 05/31/03 End: 12/31/04 Due: 12/31/05

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00798213 Org: User:
Start: 01/31/09 End: 04/30/10 Due: 04/30/11

A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)

Phase: N/A Priority: Normal
NCT ID: NCT00960934 Org: User:
Start: 10/31/09 End: 12/31/10 Due: 12/31/11

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Phase: N/A Priority: Normal
NCT ID: NCT02370498 Org: User:
Start: 05/11/15 End: 06/10/21 Due: 06/10/22

Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

Phase: N/A Priority: Normal
NCT ID: NCT01532973 Org: User:
Start: 02/16/12 End: 05/17/13 Due: 05/17/14

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Phase: N/A Priority: Normal
NCT ID: NCT06780137 Org: User:
Start: 02/27/25 End: 08/31/29 Due: 08/31/30

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Phase: N/A Priority: Normal
NCT ID: NCT01120600 Org: User:
Start: 06/09/10 End: 07/22/13 Due: 07/22/14

Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)

Phase: N/A Priority: Normal
NCT ID: NCT01017458 Org: User:
Start: 06/30/07 End: 08/31/08 Due: 08/31/09

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

Phase: N/A Priority: Normal
NCT ID: NCT05612035 Org: User:
Start: 03/16/23 End: 10/07/29 Due: 10/07/30

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Phase: N/A Priority: Normal
NCT ID: NCT02059187 Org: User:
Start: 02/11/14 End: 03/11/15 Due: 03/11/16

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Phase: N/A Priority: Normal
NCT ID: NCT02142738 Org: User:
Start: 08/25/14 End: 05/27/21 Due: 05/27/22

Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

Phase: N/A Priority: Normal
NCT ID: NCT02318667 Org: User:
Start: 02/27/15 End: 09/05/17 Due: 09/05/18

EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)

Phase: N/A Priority: Normal
NCT ID: NCT01110616 Org: User:
Start: 06/30/10 End: 10/31/10 Due: 10/31/11

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Phase: N/A Priority: Normal
NCT ID: NCT06890884 Org: User:
Start: 04/11/25 End: 12/16/32 Due: 12/16/33

A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01055340 Org: User:
Start: 04/30/10 End: 06/30/10 Due: 06/30/11

A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)

Phase: N/A Priority: Normal
NCT ID: NCT01335607 Org: User:
Start: 04/30/11 End: 05/31/11 Due: 05/31/12

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Phase: N/A Priority: Normal
NCT ID: NCT03635567 Org: User:
Start: 10/25/18 End: 06/04/24 Due: 06/04/25

Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

Phase: N/A Priority: Normal
NCT ID: NCT02155335 Org: User:
Start: 07/01/14 End: 10/05/15 Due: 10/05/16

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Phase: N/A Priority: Normal
NCT ID: NCT01122667 Org: User:
Start: 06/30/10 End: 06/30/11 Due: 06/30/12

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Phase: N/A Priority: Normal
NCT ID: NCT00732810 Org: User:
Start: 07/31/08 End: 06/30/11 Due: 06/30/12

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Phase: N/A Priority: Normal
NCT ID: NCT02630706 Org: User:
Start: 12/16/15 End: 12/27/17 Due: 12/27/18

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Phase: N/A Priority: Normal
NCT ID: NCT00705107 Org: User:
Start: 11/30/04 End: 11/30/07 Due: 11/30/08

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

Phase: N/A Priority: Normal
NCT ID: NCT00725452 Org: User:
Start: 10/31/06 End: 06/30/10 Due: 06/30/11

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Phase: N/A Priority: Normal
NCT ID: NCT00432731 Org: User:
Start: 12/31/04 End: 09/30/05 Due: 09/30/06